Chugai Pharma U.K. Ltd. and Chugai Pharma Europe Ltd believe it is important to be transparent regarding interactions with Healthcare Professionals, Healthcare Organisations, the NHS and with Patient Organisations.

 

• Payments made to Healthcare Professionals and Healthcare Organisations will be disclosed via central portals organised and managed by The Irish Pharmaceutical Healthcare Association (IPHA) and The Association of the British Pharmaceutical Industry (ABPI) for payments made in Ireland and the UK respectively. These payments have been publicly available since July 1st 2016 and are updated annually. Methodological notes will give support to any reader to better understand the manner in which Chugai manages such payments.

 

• Payments made to Patient Organisations are disclosed via the company website. Details will be given as to the Patient Organisation, the nature of the engagement, the amount paid and the percentage this payment represents of the annual income of the Patient Organisation and updated annually.

 

• Patients benefit from the collaboration between Healthcare Professionals and the pharmaceutical industry through the development and appropriate use of innovative treatments that aim to improve patient care. Healthcare Professionals and pharmaceutical companies regularly work together throughout the life of a medicine. As an integral part of the medicines development process it is entirely appropriate that fees are paid to Healthcare Professionals to reimburse them for their time and expertise.

 

• The pharmaceutical industry is committed to ensuring the transparency of relationships with Healthcare Professionals. Across Europe the industry announced its intention to disclose payments to Healthcare Professionals at an individual level annually.

 

• The NHS and the pharmaceutical industry share a common goal in improving patient outcomes and this has been the foundation of Joint Working projects. The potential of such projects to deliver improvements that benefit patients has been proven in a range of services and therapies. Payments relating to Joint Working agreements will be disclosed via the company website and details will be given as to the NHS partner, the nature of the engagement and the amount paid. Such information is disclosed prior to the project starting and updated throughout the course of the project.

 


 

Transparency Declaration on 2014 Spend on UK HCPs
(CPUK/NPR/0252 Date of Prep: March 2015, Re-approved 2017)

 

Transparency Declaration on 2014 Spend on Ireland HCPs
(CPUK/NPR/0256 Date of Prep: March 2015, Re-approved 2017)

 

Transparency Declaration on 2015 Spend on Patient Organisations
(CPUK/NPR/0471 Date of Prep: April 2016)

 

Transparency Declaration on 2016 Spend on Patient Organisations
(CPUK/NPR/0631 Date of Prep: March 2017)

 

Transparency Declaration on 2017 Spend on Patient Organisations
(CPUK/NPR/0794 Date of Prep: March 2018)

 

Chugai Methodology for Disclosure of Transfers of Value
(CPUK/NPR/0632 Date of Prep: March 2017)